The Eastern Cooperative Oncology Group (ECOG) performance status is a scale used to assess how a patient’s disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.
The Brief Fatigue Inventory is a simple yet sensitive tool that allows the severity and impact of cancer-related fatigue to be assessed.
No publications this month related to supportive care in myeloma
Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Giles SL et al. Clin Radiol. 2015 Mar 19. pii: S0009-9260(15)00074-4. doi: 10.1016/j.crad.2015.02.013. [Epub ahead of print]. The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Franssen LE et al. Bone Marrow Transplant. 2015 Mar 23. doi: 10.1038/bmt.2015.48.…
DetailsTranslocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. Bochtler T et al. J Clin Oncol. 2015 Mar 16. pii: JCO.2014.57.4947. [Epub ahead of print]. Extracorporeal Membrane Oxygenation as Bridge-to-Decision in Acute Heart Failure due to Systemic Light-Chain Amyloidosis. Mancio Silva J et al. Am J Case Rep. 2015 Mar 24;15:174-81.…
DetailsPhase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Seggewiss-Bernhardt R et al. Cancer. 2015 Mar 24. doi: 10.1002/cncr.29339. [Epub ahead of print]. O7.3BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies. Herait…
DetailsClass IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Kikuchi S et al. Leukemia. 2015 Mar 24. doi: 10.1038/leu.2015.83. [Epub ahead of print]. Structure-activity relationships of benzhydrol derivatives based on 1′-acetoxychavicol acetate (ACA) and their inhibitory activities on multiple myeloma cell growth via inactivation of the NF-κB pathway. Misawa T et al. Bioorg Med Chem. 2015 Mar 7. pii: S0968-0896(15)00143-1. doi:…
DetailsPanobinostat Approved for Multiple Myeloma. [No authors listed. Cancer Discov. 2015 Mar 23. [Epub ahead of print]. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma. Glavey SV et al. Expert Rev Hematol. 2015 Mar 24:1-3. [Epub ahead of print]. Recent advances in multiple myeloma. Kohgo Y et al. Int J Clin Oncol. 2015 Mar 20. [Epub ahead of print]. Patterns of total cost…
DetailsPhase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Roy V et al. Blood Cancer J. 2015 Mar 20;5:e294. doi: 10.1038/bcj.2015.23. Phase III trial of bortezomib, cyclophosphamide, dexamethasone (VCD) versus bortezomib, doxorubicin, dexamethasone (PAd) in newly-diagnosed myeloma. Mai EK et al. Leukemia. 2015 Mar 19. doi: 10.1038/leu.2015.80. [Epub…
Details
